INSULET CORPORATION’S DEDICATION TO INNOVATION
Insulet has changed the lives of individuals with insulin-dependent diabetes across the globe with the Omnipod® Insulin Management System. In addition to our new Omnipod DASH™ Insulin Management System, we are also actively developing innovative new products to reduce the burden of diabetes management and improve quality of life for people with diabetes.
Insulet Product Roadmap
Insulet is working to bring innovation to life
Omnipod DASH™ Insulin Management System
The Omnipod DASHTM System is a wearable insulin pump that delivers up to 200 units of U-100 insulin through customizable basal rates and bolus amounts. The system consists of the Personal Diabetes Manager (PDM) and the Pod, which is worn on body and delivers non-stop insulin for three days.* The Omnipod DASHTM System has been tested and found to be safe for use with the following U-100 insulin: Novolog®, Humalog®, Apidra®, or Admelog®.
Omnipod HORIZON™ Automated Glucose Control System
Insulet is working on the Omnipod HORIZONTM System to commercialize a hybrid closed loop system. The intended design of the system is to utilize estimated glucose values from a Continuous Glucose Monitor (CGM) to predict future blood glucose and adjust insulin delivery. The HORIZONTM System will leverage the technology of the DASHTM Insulin Management System on a smart phone.
*The Omnipod HORIZON™ System is an investigational device, limited by United States Law to Investigational Use
Insulet collaboration with Tidepool Loop Program
Insulet announced it will be working with Tidepool, a non-profit organization that is working on an open-source, iOS based app and algorithm. The algorithm, called Loop, is owned by Tidepool and runs on a mobile app on an iPhone. Insulet and Tidepool are developing an automated insulin delivery system utilizing the Tidepool Loop algorithm, an Omnipod® Pod, and a Continuous Glucose Monitor. Loop is intended to be delivered by Tidepool as a supported, FDA-regulated mobile app in the App Store.
*Not FDA approved. Not available for sale in the US
Insulet is working on bringing a version of the Omnipod® System to market that will be indicated for use with concentrated insulins. This product aims to fill the need for higher insulin requiring patients, both Type 1 and Type 2.
*Not 510(k) cleared. Not available for sale in the US
“We have installed our first highly automated manufacturing line at our new Acton, Massachusetts corporate headquarters and we are on track to begin production this quarter,” said Shacey Petrovic, President and Chief Executive Officer. “Investing in this state-of-the-art U.S. manufacturing facility allows us to increase our capacity to better support our Podder™ community, create local jobs and further strengthen our commitment to Massachusetts. We are thrilled to bring Pod manufacturing and jobs to Massachusetts and a truly innovative product to our customers.”
President and Chief Executive Officer
Important Safety Information: The Omnipod® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin and for the quantitative measurement of glucose in fresh whole capillary blood from the finger. The glucose measurements should not be used for the diagnosis or screening for diabetes. The Personal Diabetes Manager (PDM) glucose meter is intended for single-patient use and should not be shared. The Omnipod® System has been tested and found to be safe for use with the following U-100 insulin: Novolog®/NovoRapid®, Humalog®, or Apidra®. Refer to the Omnipod® Insulin Management System User Guide at myomnipod.com for complete safety information including indications, contraindications, warnings, cautions, and instructions.